on September 14, 2006
Published online before print September 14, 2006, doi: 10.1161/01.ATV.0000245793.83158.06
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 14, 2006
Accepted on August 30, 2006
Matrix Gla Protein Is Associated With Risk Factors for Atherosclerosis but not With Coronary Artery Calcification
Christopher J. O’Donnell *;
From Framingham Heart Study (C.J.O., P.W.F.W., M.G.L.), Framingham, Mass; Cardiology Division (C.J.O.) and Department of Radiology (M.F., U.H.), Massachusetts General Hospital, Boston, Mass; Department of Radiology (M.E.C.), Beth Israel-Deaconess Hospital, Boston, Mass; Institute for Aging Research, Hebrew SeniorLife (D.P.K.), Boston, Mass; Department of Biostatistics (D.R.G., L.A.C.), Boston University School of Public Health, Boston, Mass; the Massachusetts Veterans Epidemiology Research and Information Center [MAVERIC] (D.R.G.), Boston, Mass; USDA Human Nutrition Research Center on Aging (B.D.H., S.B., M.K.S.), Tufts University, Boston, Mass; Department of Biology, University of California at San Diego (P.A.P., M.K.W.), La Jolla, Calif; and the National Heart, Lung, and Blood Institute (C.J.O.), Bethesda, Md.
* To whom correspondence should be addressed. E-mail: odonnellc{at}nhlbi.nih.gov.
Objectives--Atherosclerotic coronary artery calcification (CAC) is associated with increased coronary heart disease (CHD) risk. Matrix Gla protein (MGP) is an inhibitor of calcification in vivo. However, little is known regarding the distribution of circulating MGP and its associations with CHD risk factors or with CAC in humans.
Methods and Results--Serum MGP concentrations were determined in 2 independent populations of men and women free of clinically apparent cardiovascular disease: study A, n=316, mean age 58 years, and study B, n=452, mean age 68 years. CAC was determined by computed tomography. Mean MGP concentrations were 98.4 and 198 ng/mL in men, and 97.4 and 201 ng/mL in women, in study A and study B, respectively. In both cohorts, MGP levels were higher with increasing age. In age-adjusted analyses, there was an association of circulating MGP with increasing Framingham CHD risk score (in study A, P=0.003 in men and P=0.016 in women, respectively; in study B, a nonsignificant increase in men and P=0.05 in women, respectively). Significant associations of circulating MGP with high-density lipoprotein and other individual CHD risk factors were also noted in both cohorts. There were no consistent associations between MGP and CAC after adjustment for CHD risk score in the 2 cohorts.
Conclusions--MGP is associated with individual CHD risk factors and the Framingham CHD risk score in men and women free of clinically apparent CHD. The relation of MGP with CAC deserves further study in larger populations.
Key words: atherosclerosis • coronary artery calcification • coronary risk factors • matrix Gla protein
This article has been cited by other articles:
 |
|
 |
|
  R. C. Shroff, V. Shah, M. P. Hiorns, M. Schoppet, L. C. Hofbauer, G. Hawa, L. J. Schurgers, A. Singhal, I. Merryweather, P. Brogan, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3263 - 3271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Danziger Vitamin K-dependent Proteins, Warfarin, and Vascular Calcification Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1504 - 1510. [Abstract] [Full Text] [PDF]
|
|